Implementation of vaccination programs has had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing childhood and adult mortality and drastically improving the quality of life worldwide. Individuals can receive a wide range of vaccinations throughout their life that prevent infections and the diseases associated with chronic infections. Although vaccination guidelines may offer strong recommendations for certain vaccines, others are administered at the discretion of the prescribing physician and patient. As such, commercial opportunity exists for vaccines that can offer meaningful advantages over current agents. Despite notable competition, both the adult and pediatric segments of the vaccines market remain attractive areas for the development of new prophylactic options.

QUESTIONS ANSWERED

  • What are the sizes of the populations eligible for key vaccination programs in the G7?
  • Who are the key decision makers for vaccine purchasing and administration, and how does this role vary by geography?
  • What are the key drivers of brand preference in a given vaccine market?
  • Which pathogens have the greatest unmet need for a new or improved vaccine? Which patient pools do experts indicate will be eligible for these vaccines?
  • How will the current vaccine pipeline fulfill areas of unmet need in the vaccine market?
  • How will key current and emerging vaccines perform commercially?

PRODUCT DESCRIPTION

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Emerging Vaccines - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • January 2021
    • Market Outlook
      • Key Findings
        • Market Overview
        • Regional Vaccine Sales in the Major Pharmaceutical Markets, 2017-2027
        • SWOT Analysis
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Vaccines?
        • What Factors Are Constraining the Market for Vaccines?
        • Key Market Events for Vaccines: 2017-2027
      • Segment-Specific Trends
        • Major-Market Sales for Vaccines Against Human Papillomavirus, 2017-2027
        • Major-Market Sales for Vaccines Against Herpes Zoster, 2017-2027
        • Major-Market Sales for Vaccines Against Meningococcus B, 2017-2027
        • Major-Market Sales for Vaccines Against Meningococcus ACWY, 2017-2027
        • Major-Market Sales for Vaccines Against Pneumococcus, 2017-2027
        • Major-Market Sales for Vaccines Against Seasonal Influenza, 2017-2027
        • Major-Market Sales for Vaccines Against Hepatitis B Virus, 2017-2027
        • Major-Market Sales for Vaccines Against Respiratory Syncytial Virus, 2017-2027
      • Alternative Market Scenarios
      • Forecast
        • Market Forecast Assumptions
        • Market Forecast Dashboard
        • Sales of Influenza Vaccines in the Major Pharmaceutical Markets: 2017-2027
        • Sales of Pneumococcal Vaccines in the Major Pharmaceutical Markets: 2017-2027
        • Sales of Human Papillomavirus Vaccines in the Major Pharmaceutical Markets: 2017-2027
        • Sales of Herpes Zoster Vaccines in the Major Pharmaceutical Markets: 2017-2027
        • Sales of Meningococcus B Vaccines in the Major Pharmaceutical Markets: 2017-2027
        • Sales of Meningococcus ACWY Vaccines in the Major Pharmaceutical Markets: 2017-2027
        • Sales of Hepatitis B Virus Vaccines in the Major Pharmaceutical Markets: 2017-2027
        • Sales of Respiratory Syncytial Virus Vaccines in the Major Pharmaceutical Markets: 2017-2027
      • Vaccine Technologies
        • Immunology and Vaccine-Preventable Diseases
          • Active Immunity
            • Classification of Vaccines
              • Live Attenuated Vaccines
                • Inactivated Vaccines
                  • Polysaccharide Vaccines
                    • Vaccines Based on Bacterial Proteins, Polysaccharides, and Protein-Conjugated Polysaccharides
                      • Recombinant Vaccines
                        • Adjuvants
                          • Genetic Vaccines
                            • DNA Vaccine
                            • mRNA Vaccine
                        • Epidemiology
                          • Key Findings
                            • Epidemiology Populations
                              • Definition
                              • Methods
                              • Sources Used for the Population Eligible for the RSV Vaccine
                              • Total Number of Persons Eligible for the RSV Vaccine: 2018-2028 (in Thousands)
                              • Definition
                              • Methods
                              • Sources Used for the Population Eligible for the HBV Vaccine
                              • Total Number of Persons Eligible for the Hepatitis B Vaccine: 2018-2028 (in Thousands)
                              • Disease Definition
                              • Methods
                              • Sources Used for the Population Eligible for the Human Papillomavirus Vaccine
                              • Total Number of Persons Eligible for the Human Papillomavirus Vaccine: 2018-2028 (in Thousands)
                              • Disease Definition
                              • Methods
                              • Sources Used for the Population Eligible for the Shingles Vaccine
                              • Total Number of Persons Eligible for the Shingles Vaccine: 2017-2027 (in Thousands)
                              • Disease Definition
                              • Methods
                              • Sources Used for the Population Eligible for the Influenza Vaccine
                              • Total Number of Persons Eligible for the Influenza Vaccine: 2017-2027 (in Thousands)
                              • Disease Definition
                              • Methods
                              • Sources Used for the Population Eligible for the Pneumococcal Vaccine
                              • Total Number of Persons Eligible for the Pneumococcal Vaccine: 2017-2027 (in Thousands)
                              • Disease Definition
                              • Methods
                              • Sources Used for the Population Eligible for the Meningococcal B Vaccine
                              • Total Number of Persons Eligible for a Meningococcal B Vaccine: 2017-2027 (in Thousands)
                              • Disease Definition
                              • Methods
                              • Sources Used for the Population Eligible for the Meningococcal A, C, W, and Y Vaccine
                              • Total Number of Persons Eligible for the Meningococcus A, C, W, and Y Vaccine: 2017-2027 (in Thousands)
                              • Sources Used for Vaccination Rates
                              • Number of Vaccinated Patients: 2017-2027 (in Thousands)
                          • Current Treatment
                            • Key Findings
                              • Treatment Goals
                                • Key Endpoints Used in Clinical Trials of Vaccines
                              • Key Current Therapies
                                • Overview
                                • Mechanism of Action of Key Current Vaccines
                                • Current Vaccines
                                • Advantages and Disadvantages of Gardasil 9
                                • Expert Insight: Use of Gardasil 9 for the Prevention of HPV
                                • Advantages and Disadvantages of Gardasil
                                • Expert Insight: Use of Gardasil for the Prevention of HPV
                                • Advantages and Disadvantages of Cervarix
                                • Expert Insight: Use of Cervarix in the Prevention of HPV
                                • Vaccination Guidelines
                                • Country-Specific HPV Vaccination Guidelines
                                • Factors Influencing Vaccine Selection in HPV
                                • Advantages and Disadvantages of Prevnar 13
                                • Expert Insight: Use of Prevnar 13 for the Prevention of Pneumococcus
                                • Advantages and Disadvantages of Pneumovax 23
                                • Expert Insight: Use of Pneumovax 23 for the Prevention of Pneumococcus
                                • Vaccination Guidelines
                                • Country-Specific Pneumococcal Vaccination Guidelines
                                • Factors Influencing Vaccine Selection for Pneumococcus
                                • Meningococcal Vaccines
                                • Advantages and Disadvantages of Menveo
                                • Advantages and Disadvantages of Menactra
                                • Advantages and Disadvantages of Nimenrix
                                • Expert Insight: Meningococcal Vaccines
                                • Advantages and Disadvantages of Bexsero
                                • Expert Insight: Use of Bexsero in the Prevention of Meningococcus
                                • Advantages and Disadvantages of Trumenba
                                • Expert Insight: Use of Trumenba in the Prevention of Meningococcus
                                • Vaccination Guidelines
                                • Country-Specific Meningococcal Vaccination Guidelines
                                • Factors Influencing Vaccine Selection for Meningococcus
                                • Expert Insight: Use of Major Seasonal Influenza Brands in the Prevention of Seasonal Influenza
                                • Advantages and Disadvantages of Fluzone
                                • Advantages and Disadvantages of Flulaval
                                • Advantages and Disadvantages of Fluarix
                                • Current Minor Vaccines Used for Seasonal Influenza
                                • Vaccination Guidelines
                                • Factors Influencing Vaccine Selection for Seasonal Influenza
                                • Advantages and Disadvantages of Engerix-B
                                • Expert Insight: Use of Engerix-B in the Prevention of Hepatitis B Virus
                                • Advantages and Disadvantages of Recombivax HB / HBVaxPRO
                                • Expert Insight: Use of Recombivax HB / HBVaxPRO in the Prevention of Hepatitis B Virus Infection
                                • Advantages and Disadvantages of Heplisav-B
                                • Expert Insight: Use of Heplisav-B in the Prevention of Hepatitis B Virus
                                • Vaccination Guidelines
                                • Factors Influencing Vaccine Selection for Hepatitis B Virus
                            • Unmet Need Overview
                              • Current and Future Attainment of Unmet Needs for Vaccines
                                • Top Unmet Needs for Vaccines: Current and Future Attainment
                            • Emerging Therapies
                              • Key Findings
                                • Pipeline Trends in Vaccines
                              • Key Emerging Therapies
                                • Notable Developments Among Key Emerging Vaccines
                                • Key Vaccines in Development
                                • Estimated Launch Dates of Key Emerging Vaccines
                                • Oral Flu Vaccine Profile
                                • Analysis of the Clinical Development Program for Oral Flu Vaccine
                                • Expectations for Launch and Sales Opportunity of Oral Flu Vaccine for Seasonal Influenza
                                • M-001 Profile
                                • M-001 Clinical Development
                                • Expectations for Launch and Sales Opportunity of M-001 for Seasonal Influenza
                                • NasoVAX Profile
                                • NasoVAX Clinical Development
                                • Expectations for Launch and Sales Opportunity of NasoVAX for Seasonal Influenza
                                • NanoFlu Profile
                                • NanoFlu Clinical Development
                                • Expectations for Launch and Sales Opportunity of NanoFlu for Seasonal Influenza
                                • Expert Insight: Emerging Vaccines for the Prevention of Seasonal Influenza
                                • V-114 Profile
                                • V-114 Clinical Development
                                • Expert Insight: Use of V-114 in the Prevention of Pneumococcus
                                • Expectations for Launch and Sales Opportunity of V-114 for the Prevention of Pneumococcus
                                • ResVax Profile
                                • ResVax Clinical Development
                                • Expectations for Launch and Sales Opportunity of ResVax for RSV
                                • MVA-BN RSV Profile
                                • MVA-BN RSV Clinical Development
                                • Expectations for Launch and Sales Opportunity of MVA-BN-RSV for RSV
                                • Expert Insight: Emerging RSV Vaccines
                                • Sci-B-Vac Profile
                                • Sci-B-Vac Clinical Development
                                • Expert Insight: Use of Sci-B-Vac in the Prevention of HBV
                                • Expectations for Launch and Sales Opportunity of Sci-B-Vac for HBV
                              • Early-Phase Pipeline Analysis
                                • Notable Developments in the Early-Phase Vaccine Pipeline
                                • Select Vaccines in Early-Phase Development
                            • Access & Reimbursement Overview
                              • Region-Specific Reimbursement Practices
                                • Key Market Access Considerations for Vaccines: United States
                                • General Reimbursement Environment: United States
                                • Key Market Access Considerations for Vaccines: EU5
                                • General Reimbursement Environment: EU5
                                • Key Market Access Considerations for Vaccines: Japan
                                • General Reimbursement Environment: Japan
                            • Appendix
                              • Key Abbreviations Related to Vaccines
                              • Brands and Marketers of Key Vaccines
                              • Vaccines Bibliography

                          Author(s): Natasha Bardhan, M.Pharm.; Alison Isherwood, M.Sc., M.Res., Ph.D.

                          Natasha Bardhan is an Associate Analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. She conducts primary and secondary research for a range of antibacterial and antiviral indications, as well as niche and rare diseases. She has also authored content on the treatment of HABP/VABP gram-negative infections. She holds a bachelor’s degree in pharmacy from the Delhi Institute of Pharmaceutical Sciences and Research and a master’s degree in pharmaceutics from Amity University in Noida.

                          Alison Isherwood, M.Sc., M.Res., Ph.D., is a senior director on the Epidemiology team at Clarivate. She specializes in female cancers, biomarker, and infectious disease epidemiology, particularly involving the impact of vaccination. She holds a B.Sc. in medical microbiology, a master’s degree in research in the life sciences (specializing in virology and parasitology), and an M.Sc. in epidemiology, all from the University of Edinburgh. She also holds a Ph.D. in molecular virology from the University of Reading in England.